FGF21 alleviates endothelial mitochondrial damage and prevents BBB from disruption after intracranial hemorrhage through a mechanism involving SIRT6

Table 1 Characteristics of the study population

	\(\Delta\) GCS > 0	\(\Delta\) GCS < 0	Crude OR (95%CI)	Crude P value	Adjusted OR (95% CI)	Adjusted P value
Gender
Female	17 (50%)	20 (46.51%)	1.150 (0.467,2.830)	0.761
Male	17 (50%)	23 (53.49%)	1.150 (0.467,2.830)	0.761
Smoking
No	21 (61.76%)	16 (37.21%)	2.726 (1.078,6.894)	0.034	0.095 (0.004,2.262)	0.146
Yes	13 (38.24%)	27 (62.79%)	2.726 (1.078,6.894)	0.034	0.095 (0.004,2.262)	0.146
Hypertension
No	24 (70.59%)	20 (46.51%)	2.76 (1.067,7.140)	0.036	1.875 (0.116,30.174)	0.658
Yes	10 (29.41%)	23 (53.49%)	2.76 (1.067,7.140)	0.036	1.875 (0.116,30.174)	0.658
Dyslipidaemia
No	18 (52.94%)	22 (51.16%)	1.074 (0.436,2.643)	0.877
Yes	16 (47.06%)	21 (48.84%)	1.074 (0.436,2.643)	0.877
Diabetes
No	22 (64.71%)	18 (41.86%)	2.546 (1.006,6.443)	0.048	1,867 (0.044,78.763)	0.744
Yes	12 (35.29%)	25 (58.14%)	2.546 (1.006,6.443)	0.048	1,867 (0.044,78.763)	0.744
Age	54.35 \(\pm\) 9.84	58.56 \(\pm\) 11.50	1.037 (0.993,1.083)	0.097
BMI	23.76 \(\pm\) 2.487	23.70 \(\pm\) 2.50	0.989 (0.824,1.187)	0.906
Hematoma volume (ml)	14.62 \(\pm\) 2.57	15.53 \(\pm\) 2.78	1.138 (0.958,1.351)	0.141
FGF21 (pg/ml)	434.15 \(\pm\) 99.6	250.84 \(\pm\) 125.8	0.99 (0.98,0.99)	< 0.001	0.981 (0.97,0.99)	< 0.001

ISSN: 1528-3658